– CANADA, Halifax – MedMira Inc. (TSX: MIR) today announced the appointment of Pascale Nini to its Board as an Independent Director.
Concurrently, Thomas Bergmann has been appointed as the independent Chairman.
“We are delighted to bring Ms. Nini to the board and gain access to her experience, network and expertise for our future technologies. While MedMira’s inventors and founders have created an excellent and proven technology and developed several lines of high quality products, the next stage of the Company is to further expand in new areas,” said Board Chairman, Thomas Bergmann.
He added, “As president and CEO of Immervision, she understands that success comes not only from innovation but also from perseverance, adaptation, and a solid network in the market and with investors. Immervision’s success has provided her with the credibility and reputation with governmental institutions as well as with the investor community in Canada and the USA.”
About Pascale Nini
Pascale Nini has successfully built the company Immervision which has become an international leader in defining an intelligent vision for all new devices in any industry such as mobile, automotive, robots, aerospace, IoT, and security. With Immervision, Ms. Nini has proven to lead innovation to commercial success. In addition, Ms. Nini’s entrepreneurial accomplishments have created a significant network in North America which will aid to MedMira’s future in various aspects prudent to future growth. Ms. Nini also serves on the boards of QuiqMeds Inc. and CPQ (Conseil du patronat du Québec).
“It is with great pleasure to join the board of MedMira as I see endless potential with its RVF Technology and its associated products. In addition, MedMira’s latest patented technology MiRQ will further expand its outreach in current and new markets. I am proud to support the Board and the management with my network and experience during the next steps of the Company’s growth,” said Pascale Nini.
About MedMira
MedMira is a leading developer and manufacturer of Rapid Vertical Flow Technology diagnostics. The Company’s tests provide hospitals, labs, clinics, and individuals with instant disease diagnoses, such as HIV, Syphilis, Hepatitis, and SARS-CoV-2, in just three easy steps. The Company’s tests are sold globally under the REVEAL, REVEALCOVID-19, Multiplo, and Miriad brands. Based on its patented Rapid Vertical Flow Technology, MedMira’s rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China, and the European Union. MedMira’s corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada.
For more information: https://www.medmira.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
